Drug Profile
Glembatumumab vedotin - Celldex Therapeutics Inc
Alternative Names: CDX-011; CR 011 ADC; CR 011-vcMMAE; CR011-vcMMAE immunotoxin; Glemba; Glembatumumab; GVLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator CuraGen Corporation
- Developer Celldex Therapeutics Inc; National Cancer Institute (USA)
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Brain cancer; Breast cancer; Malignant melanoma; Osteosarcoma; Squamous cell cancer; Uveal melanoma